BioCentury | Oct 23, 2006
Company News

Quantum Genomics management update

...Metabolic Hired: Jean-Pierre Riffaud as head of preclinical development, formerly head of preclinical development at Procyon Biopharma Inc.'s...
BioCentury | Oct 16, 2006
Product Development

Differentiating Ambrilia's PI

...targeting technology delivering doxorubicin (TVT-Dox), which is in preclinical testing for solid tumors. AMB, formerly Procyon BioPharma Inc....
BioCentury | Oct 16, 2006
Company News

Ambrilia, Merck deal

...treat HIV: an integrase inhibitor program and a peptide program. Ambrilia was formerly known as Procyon...
BioCentury | Oct 13, 2006
Company News

Merck, Ambrilia HIV deal

...fall within the scope of the AMB protease inhibitor program. Ambrilia was formerly known as Procyon...
BioCentury | Mar 6, 2006
Company News

Cellpep SA, Procyon deal

...trades on the Toronto Stock Exchange under the symbol AMB. Cellpep SA , Paris, France Procyon BioPharma Inc....
BioCentury | Jan 23, 2006
Company News

Cellpep SA, Procyon deal

...Ambrilia. Cellpep President and CEO Bonabes Rouge will become CSO. Cellpep SA , Paris, France Procyon BioPharma Inc....
BioCentury | Jan 20, 2006
Financial News

Procyon raises C$18.1M, plans acquisition

...Cancer and infectious disease company Procyon (TSX:PBP) raised C$18.1 million ($15.6 million) in a private placement...
BioCentury | Dec 12, 2005
Clinical News

PPL-100: Phase I start

...start this month a placebo-controlled, dose-escalation, Canadian Phase I trial in 40 healthy male volunteers. Procyon BioPharma Inc....
BioCentury | Dec 12, 2005
Clinical News

PSP94 serum-based immunoassay diagnostic data

...while PSA and FTPSA could not. Data will be published in the Journal of Urology. Procyon BioPharma Inc....
BioCentury | Nov 21, 2005
Clinical News

PPL-100: Phase I start

...PPl-100 at 100, 300, 600, 1,200 or 2,400 mg with and without 100 mg Ritonavir. Procyon BioPharma Inc....
Items per page:
1 - 10 of 87
BioCentury | Oct 23, 2006
Company News

Quantum Genomics management update

...Metabolic Hired: Jean-Pierre Riffaud as head of preclinical development, formerly head of preclinical development at Procyon Biopharma Inc.'s...
BioCentury | Oct 16, 2006
Product Development

Differentiating Ambrilia's PI

...targeting technology delivering doxorubicin (TVT-Dox), which is in preclinical testing for solid tumors. AMB, formerly Procyon BioPharma Inc....
BioCentury | Oct 16, 2006
Company News

Ambrilia, Merck deal

...treat HIV: an integrase inhibitor program and a peptide program. Ambrilia was formerly known as Procyon...
BioCentury | Oct 13, 2006
Company News

Merck, Ambrilia HIV deal

...fall within the scope of the AMB protease inhibitor program. Ambrilia was formerly known as Procyon...
BioCentury | Mar 6, 2006
Company News

Cellpep SA, Procyon deal

...trades on the Toronto Stock Exchange under the symbol AMB. Cellpep SA , Paris, France Procyon BioPharma Inc....
BioCentury | Jan 23, 2006
Company News

Cellpep SA, Procyon deal

...Ambrilia. Cellpep President and CEO Bonabes Rouge will become CSO. Cellpep SA , Paris, France Procyon BioPharma Inc....
BioCentury | Jan 20, 2006
Financial News

Procyon raises C$18.1M, plans acquisition

...Cancer and infectious disease company Procyon (TSX:PBP) raised C$18.1 million ($15.6 million) in a private placement...
BioCentury | Dec 12, 2005
Clinical News

PPL-100: Phase I start

...start this month a placebo-controlled, dose-escalation, Canadian Phase I trial in 40 healthy male volunteers. Procyon BioPharma Inc....
BioCentury | Dec 12, 2005
Clinical News

PSP94 serum-based immunoassay diagnostic data

...while PSA and FTPSA could not. Data will be published in the Journal of Urology. Procyon BioPharma Inc....
BioCentury | Nov 21, 2005
Clinical News

PPL-100: Phase I start

...PPl-100 at 100, 300, 600, 1,200 or 2,400 mg with and without 100 mg Ritonavir. Procyon BioPharma Inc....
Items per page:
1 - 10 of 87